Bcr-Abl
Les inhibiteurs de Bcr-Abl sont des thérapies ciblées qui inhibent la protéine de fusion Bcr-Abl, formée à la suite de la translocation du chromosome Philadelphie et moteur de la leucémie myéloïde chronique (LMC). Cette protéine influence également l'angiogenèse, contribuant à la progression tumorale. Les inhibiteurs de Bcr-Abl sont cruciaux dans le traitement de la LMC et sont explorés pour leur potentiel à inhiber l'angiogenèse dans divers cancers. Chez CymitQuimica, nous offrons des inhibiteurs de Bcr-Abl de haute qualité pour soutenir vos recherches en biologie du cancer, angiogenèse et thérapies ciblées.
Produits appartenant à la catégorie "Bcr-Abl"
Trier par
63 produits dans cette catégorie.
GNF-5
CAS :GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.Formule :C20H17F3N4O3Degré de pureté :98% - 99.98%Couleur et forme :SolidMasse moléculaire :418.37Pivanex
CAS :Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.Formule :C10H18O4Degré de pureté :≥98%Couleur et forme :SolidMasse moléculaire :202.25AST 487
CAS :AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.Formule :C26H30F3N7O2Degré de pureté :98.17% - 99.56%Couleur et forme :SolidMasse moléculaire :529.56Ref: TM-T4053
1mg37,00€2mg52,00€5mg79,00€10mg119,00€25mg187,00€50mg354,00€100mg528,00€500mg1.159,00€1mL*10mM (DMSO)92,00€Multi-kinase inhibitor 1
CAS :Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Formule :C20H17F3N4O3Degré de pureté :99.34%Couleur et forme :SolidMasse moléculaire :418.37Nilotinib
CAS :Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.Formule :C28H22F3N7ODegré de pureté :99.61% - 99.83%Couleur et forme :Off-White SolidMasse moléculaire :529.52HG-7-85-01
CAS :HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.Formule :C31H31F3N6O2SDegré de pureté :98.08%Couleur et forme :SolidMasse moléculaire :608.68Imatinib impurities3
CAS :Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.Formule :C24H20ClN5ODegré de pureté :97.05%Couleur et forme :SolidMasse moléculaire :429.9Olverembatinib dimesylate
CAS :Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formule :C29H27F3N6O·2CH4O3SDegré de pureté :100% - 99.81%Couleur et forme :SolidMasse moléculaire :724.77Ref: TM-T2429
1mg39,00€2mg51,00€5mg84,00€10mg119,00€25mg229,00€50mg319,00€100mg474,00€1mL*10mM (DMSO)120,00€BCR-ABL-IN-7
CAS :BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.Formule :C19H16FN3O3SDegré de pureté :98.28%Couleur et forme :SolidMasse moléculaire :385.41Bosutinib
CAS :Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formule :C26H29Cl2N5O3Degré de pureté :98.98% - 99.9%Couleur et forme :Yellowish-Orange Or Pink To Brownish Solid Solid PowderMasse moléculaire :530.45Nocodazole
CAS :Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formule :C14H11N3O3SDegré de pureté :98% - 99.91%Couleur et forme :Physical Description White Powder (Ntp 1992)Masse moléculaire :301.32Ref: TM-T2802
5mg37,00€10mg55,00€25mg99,00€50mg168,00€100mg283,00€200mg420,00€500mg682,00€1mL*10mM (DMSO)40,00€BCR-ABL-IN-10
BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).Formule :C24H22N4O5SCouleur et forme :SolidMasse moléculaire :478.52GNF-2
CAS :GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.Formule :C18H13F3N4O2Degré de pureté :98.17% - ≥95%Couleur et forme :SolidMasse moléculaire :374.32PD180970
CAS :PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.Formule :C21H15Cl2FN4ODegré de pureté :98.47%Couleur et forme :SolidMasse moléculaire :429.27PF-06651481-00
CAS :PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.Formule :C26H29Cl2N5O3Degré de pureté :97.57%Couleur et forme :SolidMasse moléculaire :530.45N-Desmethyl imatinib
CAS :N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Formule :C28H29N7ODegré de pureté :98.60%Couleur et forme :Off-White To Pale-Yellow SolidMasse moléculaire :479.58Ref: TM-T11641
1mg92,00€5mg170,00€10mg319,00€25mg540,00€50mg777,00€100mg1.074,00€1mL*10mM (DMSO)178,00€AKE-72
CAS :AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.Formule :C30H29F3N6ODegré de pureté :98.3%Couleur et forme :SoildMasse moléculaire :546.59Radotinib
CAS :Radotinib (IY-5511), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notablyFormule :C27H21F3N8ODegré de pureté :99.13% - 99.97%Couleur et forme :SolidMasse moléculaire :530.5LXH254
CAS :LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Formule :C25H25F3N4O4Degré de pureté :98.3% - 99.92%Couleur et forme :SolidMasse moléculaire :502.49Ref: TM-T11898
1mg52,00€5mg122,00€10mg185,00€25mg363,00€50mg567,00€100mg690,00€200mg948,00€500mg1.444,00€1mL*10mM (DMSO)135,00€AT9283
CAS :AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Formule :C19H23N7O2Degré de pureté :99.83% - 99.98%Couleur et forme :SolidMasse moléculaire :381.43Ref: TM-T3068
1mg47,00€2mg60,00€5mg95,00€10mg170,00€25mg299,00€50mg499,00€100mg723,00€1mL*10mM (DMSO)97,00€Degrasyn
CAS :Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.Formule :C19H18BrN3ODegré de pureté :98.32% - 99.98%Couleur et forme :SolidMasse moléculaire :384.27Ref: TM-T6300
2mg44,00€5mg64,00€10mg97,00€25mg198,00€50mg340,00€100mg532,00€200mg747,00€1mL*10mM (DMSO)69,00€Imatinib
CAS :Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kitFormule :C29H31N7ODegré de pureté :100% - 99.94%Couleur et forme :Off White PowderMasse moléculaire :493.6Nilotinib hydrochloride
CAS :Nilotinib HCl (AMN-107 HCl), an oral Bcr-Abl inhibitor, targets neuroinflammation, cognitive issues, and chronic myelogenous leukemia.Formule :C28H23ClF3N7ODegré de pureté :100%Couleur et forme :SolidMasse moléculaire :565.98PPY A
CAS :PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase and inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl gene-transformed cellsFormule :C22H20N4O2Degré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :372.42cSRC/BCR-ABL-IN-1
cSRC/BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.Formule :C29H31Cl2N5O4Masse moléculaire :584.494Flumatinib
CAS :Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.Formule :C29H29F3N8ODegré de pureté :99.52% - 99.95%Couleur et forme :SolidMasse moléculaire :562.59Ref: TM-T4320
1mg35,00€5mg66,00€10mg87,00€25mg127,00€50mg163,00€100mg273,00€200mg409,00€500mg677,00€1mL*10mM (DMSO)87,00€Dasatinib monohydrate
CAS :Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.Formule :C22H28ClN7O3SDegré de pureté :100% - 99.68%Couleur et forme :SolidMasse moléculaire :506.03c-ABL-IN-5
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability,Formule :C19H17F2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :341.35Lyn-IN-1
CAS :Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and LynFormule :C30H31F3N8ODegré de pureté :97% - 99.33%Couleur et forme :SolidMasse moléculaire :576.62Ref: TM-T11916
1mg47,00€2mg56,00€5mg84,00€10mg124,00€25mg250,00€50mg393,00€100mg560,00€200mg815,00€1mL*10mM (DMSO)97,00€Dasatinib N-oxide
CAS :Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.Formule :C22H26ClN7O3SDegré de pureté :98.54% - 99.85%Couleur et forme :SolidMasse moléculaire :504FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44Tyrosine kinase-IN-9
CAS :Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.Formule :C20H14ClN3O3Couleur et forme :SolidMasse moléculaire :379.796AN-019
CAS :AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.Formule :C25H17F6N5ODegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :517.43Flumatinib mesylate
CAS :Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.Formule :C30H33F3N8O4SDegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :658.69Ref: TM-T7861
1mg37,00€5mg88,00€10mg133,00€25mg250,00€50mg393,00€100mg628,00€500mg1.301,00€1mL*10mM (DMSO)139,00€CZC-8004
CAS :CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.Formule :C17H16FN5Degré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :309.34Rebastinib
CAS :DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,Formule :C30H28FN7O3Degré de pureté :99.53% - 99.79%Couleur et forme :SolidMasse moléculaire :553.59GMB-475
CAS :GMB-475, a PROTAC-based BCR-ABL1 inhibitor, tackles drug resistance by promoting VHL-mediated degradation.Formule :C43H46F3N7O7SDegré de pureté :100% - 98.78%Couleur et forme :SolidMasse moléculaire :861.93Ref: TM-T8488
1mg96,00€5mg200,00€10mg350,00€25mg590,00€50mg840,00€100mg1.130,00€500mg2.308,00€1mL*10mM (DMSO)274,00€CpCDPK1/TgCDPK1-IN-1
CAS :CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.Formule :C18H17N5Degré de pureté :98.71%Couleur et forme :SolidMasse moléculaire :303.36Dasatinib
CAS :Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.Formule :C22H26ClN7O2SDegré de pureté :99.59% - 99.86%Couleur et forme :Pale-Yellow SolidMasse moléculaire :488.01PD173955
CAS :PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR andFormule :C21H16Cl2N4OSDegré de pureté :98.52% - 99.28%Couleur et forme :SolidMasse moléculaire :443.35Olverembatinib
CAS :Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Formule :C29H27F3N6ODegré de pureté :100% - 99.29%Couleur et forme :SolidMasse moléculaire :532.56Ref: TM-T3071
1mg35,00€2mg48,00€5mg70,00€10mg96,00€25mg210,00€50mg338,00€100mg535,00€1mL*10mM (DMSO)82,00€Imatinib Mesylate
CAS :Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,Formule :C29H31N7O·CH4SO3Degré de pureté :100% - 99.97%Couleur et forme :White Crystalline PowderMasse moléculaire :589.71BCR-ABL-IN-1
CAS :BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.Formule :C23H21F4N5ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :459.44AD57
CAS :AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.Formule :C22H20F3N7ODegré de pureté :98.23%Couleur et forme :SoildMasse moléculaire :455.44Ref: TM-T22552L
1mg34,00€2mg52,00€5mg116,00€10mg212,00€25mg359,00€50mg512,00€100mg695,00€200mg939,00€1mL*10mM (DMSO)134,00€Ponatinib
CAS :Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormule :C29H27F3N6ODegré de pureté :98% - 99.60%Couleur et forme :SolidMasse moléculaire :532.56AG1024
CAS :AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formule :C14H13BrN2ODegré de pureté :98% - 99.37%Couleur et forme :SolidMasse moléculaire :305.17BCR-ABL-IN-8
CAS :BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].Formule :C30H33N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :571.63Bosutinib hydrate
CAS :Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.Formule :C26H31Cl2N5O4Degré de pureté :99.87%Couleur et forme :SolidMasse moléculaire :548.46Dasatinib hydrochloride
CAS :Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).Formule :C22H27Cl2N7O2SDegré de pureté :99.88% - 99.98%Couleur et forme :SolidMasse moléculaire :524.47DPH
CAS :DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Formule :C18H13FN4O2Degré de pureté :99.72%Couleur et forme :SolidMasse moléculaire :336.32GNF-7
CAS :GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formule :C28H24F3N7O2Degré de pureté :97.05% - 99.47%Couleur et forme :SolidMasse moléculaire :547.53XL228
CAS :XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).Formule :C22H31N9ODegré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :437.54Ref: TM-T17267
1mg56,00€2mg78,00€5mg99,00€10mg149,00€25mg258,00€50mg393,00€100mg582,00€1mL*10mM (DMSO)110,00€Nilotinib monohydrochloride monohydrate
CAS :Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosineFormule :C28H22F3N7O·HCl·H2ODegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :583.99KW-2449
CAS :KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Formule :C20H20N4ODegré de pureté :98.43% - 99.89%Couleur et forme :SolidMasse moléculaire :332.4Vodobatinib
CAS :Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.Formule :C27H20ClN3O2Degré de pureté :99.06% - 99.55%Couleur et forme :SolidMasse moléculaire :453.92Ref: TM-T8882
1mg37,00€5mg79,00€10mg116,00€25mg212,00€50mg340,00€100mg528,00€500mg1.275,00€1mL*10mM (DMSO)87,00€Gypsogenin
CAS :Gypsogenin (639-14-5) is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.Formule :C30H46O4Degré de pureté :99.73%Couleur et forme :SolidMasse moléculaire :470.68Ref: TM-T25476
1mg134,00€5mg315,00€10mg469,00€25mg748,00€50mg1.064,00€100mg1.415,00€1mL*10mM (DMSO)349,00€BGG463
CAS :BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Formule :C30H29F3N6O3Degré de pureté :100% - 95.05%Couleur et forme :SolidMasse moléculaire :578.58Ref: TM-T4618
1mg62,00€2mg87,00€5mg119,00€10mg188,00€25mg350,00€50mg505,00€100mg730,00€1mL*10mM (DMSO)154,00€HG-7-86-01
CAS :HG-7-86-01 is a selective type II tyrosine kinase inhibitor with antiproliferative activity against mutant T315I- Bcr-Abl for chronic myeloid leukemia (CML).Formule :C28H21F3N6O2SDegré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :562.57Adaphostin
CAS :Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.Formule :C24H27NO4Degré de pureté :97.31%Couleur et forme :SolidMasse moléculaire :393.48cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Formule :C24H27ClN6O4Couleur et forme :SolidMasse moléculaire :498.96Asciminib
CAS :Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5-0.8nM).Formule :C20H18ClF2N5O3Degré de pureté :97.93% - 99.45%Couleur et forme :SolidMasse moléculaire :449.84Ref: TM-T5177
1mg63,00€2mg92,00€5mg127,00€10mg187,00€25mg305,00€50mg427,00€100mg630,00€500mg1.320,00€1mL*10mM (DMSO)139,00€Bafetinib
CAS :Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.Formule :C30H31F3N8ODegré de pureté :94.16% - 99.68%Couleur et forme :SolidMasse moléculaire :576.62Ref: TM-T6311
1mg37,00€2mg52,00€5mg79,00€10mg103,00€25mg159,00€50mg188,00€100mg350,00€200mg455,00€1mL*10mM (DMSO)90,00€BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formule :C22H20N4O3Couleur et forme :SolidMasse moléculaire :388.42
